• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • Clinical Trial Listings
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • Benchmark Reports
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » CEOi, NY Academy of Sciences to launch Global Alzheimer's Platform

CEOi, NY Academy of Sciences to launch Global Alzheimer's Platform

February 26, 2014
CenterWatch Staff

The Global CEO Initiative (CEOi) on Alzheimer's Disease and the New York Academy of Sciences have convened representatives from industry, academia, government and nonprofits to launch the development of a Global Alzheimer's Platform (GAP), designed to reduce the time and costs of Alzheimer's clinical trials, develop an infrastructure that promotes innovation and assure international collaboration.

"Alzheimer's is a global epidemic that must be addressed with urgency and passion. The time, cost and risk of these trials are an impediment to speedy development of innovative therapies, and thus a critical, although challenging area for innovation," said George Vradenburg, convener of the CEOi. "We look forward to working with the Foundation for NIH to take advantage of their experience in managing large-scale collaborations, such as the Accelerating Medicines Partnership (AMP), as well as the FDA to develop the infrastructure required to advance innovation in drug development. Through our collaborative efforts here in the U.S. and with emerging consortia in Europe, we believe we can design a truly global clinical trial system of speed and power."

Currently, there is no global pool of patients eligible for clinical trials that researchers can access from anywhere in the world in order to identify appropriate trial cohorts. This creates barriers that slow the pace of drug development, a problem that is further compounded by the fact that each new Alzheimer's trial starts from the beginning in order to train the study staff and create multi-centered infrastructure.

Beyond the time it takes to test an Alzheimer's drug, there also are cost concerns. A recent report conducted by RTI International at the request of the Academy found that the cost of bringing an effective Alzheimer's treatment to market currently approaches $6 billion—nearly three times the industry average for drug development.

GAP will look to address these roadblocks through four core focuses, which include:

  • Developing a global pool of eligible clinical trial candidates;
  • Speeding trial activation by establishing new international standards for trial site certification;
  • Creating a framework that will support innovative trial designs; and
  • Establishing a sustainable funding model that delivers value across the public and private sectors.

"We can no longer afford to have Alzheimer's clinical trials siloed in a few locations around the world without a means to capture the knowledge that comes from these critical human contributions," said Ellis Rubinstein, president and CEO of the New York Academy of Sciences. "Through the development of GAP, government and industry can create more effective and streamlined Alzheimer's clinical trials, and tap new sources of revenue through innovative public-private partnerships."

The development of GAP is part of a new sense of urgency brought on by the November 2013 Summit on the Path to 2025 convened by the CEOi and the Academy, and followed by the December G8 Dementia Summit held in London, where member nations committed to stopping Alzheimer's. Currently, more than 44 million people worldwide suffer from the disease at a global cost of $605 billion annually. Without a means of prevention or cure, Alzheimer's and dementia is projected to triple in size and threaten the solvency of national health care systems the world over.

The CEOi is an organization of private-sector leaders who have joined together to provide business leadership in the fight against Alzheimer's. The CEO Initiative seeks to partner with public leaders to transform the disease from a social, health and economic crisis into an opportunity for healthy aging and innovation in research and care. The CEO Initiative believes that, during this era of aging populations, it will take visionary, coordinated, goal oriented leadership of public and private leaders working together to solve challenges.

Takeda Pharmaceutical recently joined CEOi as part of its effort to spur innovations in research and accelerate a means of prevention for Alzheimer's and Dementia, building momentum behind the G8's commitment to stop the disease by 2025. Takeda, located in Osaka, Japan, is a global provider developing innovations in medicine. It joined AC Immune, Bank of America, Banner Health, GE, Home Instead Senior Care, Janssen, Eli Lilly, Merck, Nestle Health Science, Pfizer and Sanofi in the CEOi.

The New York Academy of Sciences is an independent, nonprofit organization that since 1817 has been committed to advancing science, technology and society worldwide. With 25,000 members in 140 countries, the Academy is creating a global community of science for the benefit of humanity. The Academy's core mission is to advance scientific knowledge, positively impact the major global challenges of society with science-based solutions, and increase the number of scientifically informed individuals in society at large.

    Upcoming Events

    • 16Oct

      MAGI@home Clinical Research Conference 2023

    • 25Oct

      2023 WCG Patient Forum

    • 26Oct

      FDA in 2024: What to Expect in an Election Year

    Featured Products

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    • Best Practices for Clinical Trial Site Management

      Best Practices for Clinical Trial Site Management

    Featured Stories

    • Donna Snyder

      New WCG Executive Physician Outlines Goals for Clinical Research

    • Hand Shake at Meeting

      Partnership to Bolster Trials in Low Resource Regions Kicks Off

    • Guidelines-360x240.png

      Major Industry Groups Offer Feedback on ICH’s E6(R3) Guidelines

    • AsktheExpertsBadge-360x240.png

      Ask the Experts: Monitoring

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 703.538.7600 – Toll free 888.838.5578

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing